D2B3 provides new solutions to Drug Delivery (DD= D square) across the Blood Brain Barrier (BBB= B cube). Most drugs do not cross the BBB, hence most brain diseases cannot be cured. This is a huge unmet medical need. Our product is a patent protected, fully human monoclonal antibody (Mab) that upon intravenous injection transiently and selectively opens the BBB and allows delivery of various bioactive drugs against brain cancer, metastasis, infections, and neurological diseases. D2B3 scientists developed this Mab against a target receptor on brain capillary endothelial cells, where it blocks binding of a ligand that maintains the BBB gene expression programme. By transiently blocking this ligand from binding its target receptor, D2B3 Mab create a temporary permeability window to shuttle various drugs <70kDa into the brain, followed by BBB resealing. Our drug delivery system outperforms current competition and is expected to show low toxicity in vivo. Together with Yale Venture funded CROs, we are currently conducting in vivo efficacy studies focusing on chemotherapy delivery in preclinical rodent brain cancer models. We are seeking partners interested in pursuing lead optimization, CMC and IND enabling studies.